SCHEMBL5714742

SCHEMBL5714742

O=C(Oc1ccc(CSc2ncc[nH]2)cc1)N1CCN(c2ccc(C(F)(F)F)cn2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.53
HPGD P15428 1/20 0.53
TRPV1 Q8NER1 1/20 0.46
LIPE Q05469 5/20 0.46
TRPA1 O75762 1/20 0.45
HTT P42858 3/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
BCHE P06276 1/20 0.45
LMNA P02545 4/20 0.45
ALDH1A1 P00352 2/20 0.45
MAPT P10636 2/20 0.45
POLB P06746 1/20 0.45
THRB P10828 1/20 0.45
KDM4E B2RXH2 2/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
IDE P14735 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5715018 0.92 SMN1; SMN2 (0.52) SMN1; SMN2HPGDTRPV1LIPETRPA1
SCHEMBL5714403 0.89 PANK3 (0.42) SMN1; SMN2HPGDLMNAALDH1A1MAPT
SCHEMBL5714359 0.87 PANK3 (0.44) SMN1; SMN2HPGDL3MBTL1LMNAALDH1A1
SCHEMBL5715040 0.87 TRPA1 (0.44) SMN1; SMN2TRPV1LIPETRPA1HTT
SCHEMBL5715347 0.86 HRH3 (0.41) SMN1; SMN2HPGDTRPA1HTTLMNA
SCHEMBL5715000 0.86 PANK3 (0.41) SMN1; SMN2HPGDTRPA1HTTL3MBTL1
SCHEMBL5715306 0.84 HSD17B10 (0.51) SMN1; SMN2HPGDHTTL3MBTL1LMNA
SCHEMBL5716315 0.83 SMN1; SMN2 (0.52) SMN1; SMN2HPGDTRPV1LIPETRPA1
SCHEMBL5715776 0.82 SMN1; SMN2 (0.55) SMN1; SMN2HPGDTRPV1LIPETRPA1
SCHEMBL5714721 0.81 SMN1; SMN2 (0.65) SMN1; SMN2HPGDTRPV1LIPETRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160819-A1 Substitued piperazine carbamates LIPE, PNLIP, LIPC SMN1; SMN2 2732/4885HPGD 793/4885TRPV1 1675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.